IKS Health has announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. On a consolidated basis, total income reached ₹8,205.03 million for the quarter. Profit after tax for the quarter stood at ₹1,833.28 million. Basic earnings per share were reported as ₹10.96.
Financial Performance Overview
IKS Health has released its unaudited financial results for Q3 FY2026, covering the period ended December 31, 2025. Key financial highlights from the report include:
Consolidated Results
Total income for the quarter reached ₹8,205.03 million, compared to ₹6,841.50 million for the quarter ended December 31, 2024.
Total expenses amounted to ₹5,887.37 million for the quarter.
Profit before tax was reported at ₹2,293.70 million.
Profit for the period, after tax, stood at ₹1,833.28 million, up from ₹1,296.75 million in Q3 FY2025.
Basic earnings per share were ₹10.96, compared to ₹7.80 in the corresponding quarter of the previous year.
Nine Months Ended Performance
For the nine months ended December 31, 2025, IKS Health reported:
Total income of ₹23,484.57 million compared to ₹19,787.61 million for the nine months ended December 31, 2024.
Profit after tax of ₹5,155.86 million.
Standalone Results
IKS Health’s standalone financial results for Q3 FY2026 show a profit after tax of ₹1,462.40 million. For the nine months ended December 31, 2025, the standalone profit after tax was ₹3,975.14 million.
Basic earnings per share (EPS) for the quarter were reported as ₹8.74.
Source: BSE
